Tiotropium Bromide (Spiriva)

A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Also Known As:

Spiriva; 7-((hydroxybis(2-thienyl)acetyl)oxy)-9,9-dimethyl-3-oxa-9-azoniatricyclo(3.3.1.0(2,4))nonane bromide; BA 679 BR; BA-679 BR; Tiotropium; 679 BR, BA; BA679 BR; BR, BA 679; Bromide, Tiotropium

Networked: 1259 relevant articles (290 outcomes, 541 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Kesten, Steven: 35 articles (08/2013 - 07/2002)
2.	Cazzola, Mario: 32 articles (02/2020 - 01/2004)
3.	Moroni-Zentgraf, Petra: 30 articles (01/2020 - 09/2012)
4.	Tashkin, Donald P: 30 articles (01/2017 - 01/2004)
5.	Buhl, Roland: 27 articles (11/2020 - 01/2012)
6.	Engel, Michael: 26 articles (12/2020 - 08/2011)
7.	Decramer, Marc: 25 articles (01/2016 - 01/2004)
8.	Kerstjens, Huib A M: 24 articles (01/2022 - 11/2007)
9.	Anzueto, Antonio: 19 articles (01/2021 - 09/2006)
10.	Donohue, James F: 19 articles (10/2019 - 07/2002)

Related Diseases

1.	Chronic Obstructive Pulmonary Disease (COPD) 05/01/2009 - "A large body of evidence is available at present on the safety and efficacy of tiotropium in COPD, with dry mouth being the most common adverse event. " 07/21/2014 - "To evaluate data from randomised controlled trials (RCTs) comparing the efficacy of tiotropium and placebo in patients with COPD, upon clinically important endpoints. " 07/11/2012 - "To evaluate data from randomised controlled trials (RCTs) comparing the efficacy of tiotropium and placebo in patients with COPD, upon clinically important endpoints. " 03/01/2010 - "Results of recent clinical trials support findings from earlier trials in patients with moderate to very severe COPD demonstrating significant benefits of tiotropium compared to placebo, including sustained increases in lung function, reductions in exacerbations and risk of exacerbation-related hospitalizations, and improvement in health status. " 04/02/2013 - "TIOSPIR will provide precise estimates of the relative safety and efficacy of the Respimat and HandiHaler formulations of tiotropium, assess potential dose-dependence of important outcomes and provide information on the clinical epidemiology of COPD in a large international patient cohort."
2.	Asthma (Bronchial Asthma) 01/01/2020 - "It is extremely difficult to identify a new LAMA that is more effective than tiotropium, but is it plausible that new technologies that will allow delivering the drug in a more targeted way and with a lower risk of adverse effects may represent the real progress in the use of LAMAs in asthma in the coming years." 01/01/2015 - "Tiotropium in combination with ICS plus LABA showed the similar effects with double-dose ICS plus LABA, without adverse effects, which might be the best option for optimal control of asthma." 01/01/2015 - "The results of studies on severe asthma showed that adding tiotropium to a treatment with high doses of an ICS plus LABA results in further improvement in lung function, increases the time to the first severe exacerbation of asthma and to worsening of asthma, and improves asthma control. " 12/01/2014 - "The addition of tiotropium may be beneficial for patients with poorly controlled asthma, although exacerbation or safety issues should be clarified in long-term trials before its wide use in asthma." 12/01/2020 - "Tiotropium Respimat® consistently improved FEF25-75% and FEV1 versus placebo, although in adolescents with severe asthma, the observed improvements were not statistically significant. "
3.	Dyspnea (Shortness of Breath) 09/09/2016 - "Results: In dyspneic patients, IND/GLY significantly improved Transition Dyspnea Index (TDI) total scores compared with tiotropium (0.59 units; p<0.05) and SFC (0.97 units; p<0.05), and significantly increased the likelihood of a patient achieving a 1-unit improvement in TDI compared with tiotropium (odds ratio [OR] 1.87; p<0.05). " 10/01/2010 - "Aclidinium and tiotropium also significantly increased FEV(1) (p < 0.01) and improved the perception of dyspnea compared with placebo at all measured time points from 10 minutes to 3 hours post-dose. " 03/01/2010 - "The use of tiotropium in isolation resulted in significant improvement in dyspnea at baseline (mean Medical Research Council scale score reduced from 3.0 to 2.5) and at the end of 6MWT (mean Borg scale score reduced from 6.1 to 4.5), and the differences were significant (p < 0.05 for both). " 12/01/2008 - "Tiotropium also provides superior bronchodilation and improvement in dyspnea at all time points, although onset of bronchodilation is slower than with long-acting beta(2)-agonists. " 12/01/2004 - "Clinically relevant outcomes such as the relief of dyspnea, improvement in the quality of life (health status), and reductions in the frequency and severity of acute exacerbations have been consistently obtained with tiotropium in clinical trials. "
4.	Obstructive Lung Diseases (Obstructive Lung Disease) 03/01/2016 - "Investigation of the efficacy of generic and brand-name tiotropium bromide in the management of chronic obstructive pulmonary disease: A randomized comparative trial." 12/01/2006 - "Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore." 02/01/2002 - "Tiotropium in the management of chronic obstructive pulmonary disease." 12/01/2006 - "We conducted a pooled analysis of adverse event data from 19 randomized, double-blind, placebo-controlled trials with tiotropium in patients with obstructive lung disease. " 12/01/2005 - "Does pulmonary rehabilitation give additional benefit over tiotropium therapy in primary care management of chronic obstructive pulmonary disease? "
5.	Cough 12/12/2021 - "Although most parents and physicians reported a significant benefit with tiotropium bromide, physicians particularly remarked, as their "lesson learned', on the improvement in chronic symptoms in asthmatic children, particularly those with prominent moist cough and in lung function, in those with seemingly none (or incompletely) reversible obstruction as well as the ability to decrease the ICS and/or LABA dose to lessen adverse effects. " 09/01/2018 - "Tiotropium significantly improved cough VAS, J-LCQ, and ACT scores, but not FEV1. " 09/01/2018 - "Patients with an improved cough VAS score of 15 mm or more were considered responders to tiotropium. " 01/01/2016 - "The present study was performed on rabbits to compare aclidinium and tiotropium efficacy in the downregulation of the cough reflex. " 03/01/2014 - "The aim of this study was to investigate whether tiotropium can directly modulate airway sensory nerve activity and thereby the cough reflex. "

Related Drugs and Biologics

1.	Bronchodilator Agents (Bronchodilators)
2.	Salmeterol Xinafoate (Serevent)
3.	Cholinergic Antagonists (Anticholinergics)
4.	Formoterol Fumarate (Oxis)
5.	Adrenal Cortex Hormones (Corticosteroids)
6.	Ipratropium (Ipratropium Bromide)
7.	indacaterol
8.	Tiotropium Bromide (Spiriva)
9.	Glycopyrrolate (Glycopyrronium Bromide)
10.	Fluticasone (Cutivate)

Related Therapies and Procedures

1.	Therapeutics
2.	Nebulizers and Vaporizers (Inhaler)
3.	Activities of Daily Living (ADL)
4.	Dry Powder Inhalers
5.	Respiratory Therapy (Therapy, Respiratory)